AstraZeneca's Delaware campus sold to JPMorgan

Another piece of U.S. pharma real estate has been sold. JPMorgan has bought half of AstraZeneca's ($AZN) research campus in Delaware for $44 million, according to the Philadelphia Business Journal. The property sale is part of the remake of its R&D operations, FierceBiotech points out. Story